Merck, 673000-10MG, Vacuolin-1

General description
A cell-permeable triazine based compound that inhibits Ca²⁺-dependent fusion of lysosomes with the plasma membrane and the release of lysosomal content, without affecting enlargeosomes or other membrane-bound organelles. It does not disturb the organization of the actin or tubulin cytoskeletal network, nor does it interfere with membrane traffic along the constitutive pathway from the ER to the plasma membrane.
A cell-permeable triazine-based compound that inhibits Ca²⁺-dependent exocytosis of lysosomes induced by ionomycin or plasma membrane wounding. Does not affect the resealing process and the exocytosis of enlargeosomes. It also does not disturb the organization of the actin or tubulin cytoskeletal network or interfere with membrane traffic along the constitutive pathway from the ER to the plasma membrane.
Biochem/physiol Actions
Primary Target
Ca2+-dependent fusion of lysosomes with the plasma membrane
Product does not compete with ATP.
Reversible: no
Cell permeable: yes
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
2024 CiteAb Award Winner for Supplier Succeeding in Parkinson′s Research
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)